AMG 424


AMG 424 is a novel, humanized, bispecific T cell-recruiting anti-CD3/CD38 antibody that targets multiple myeloma cancer cells through T-cell dependent redirected lysis.

In July 2020, Amgen announced a business decision not to proceed with the AMG 424 asset. Learn more...

SparkCures ID 317
Developed By Amgen
Generic Name AMG 424
Treatment Classifications
Treatment Targets

Clinical Trials


There are no resources, links or videos to display for this treatment.